SBIR Phase I: Hypertension Treatment Responder Prediction

这个小型企业创新研究(SBIR)第一阶段项目将开发软件平台Generx，以结合药物遗传学和非线性自适应算法，根据患者的具体情况优化抗高血压治疗。对精神药物奥氮平的初步研究表明，使用仅使用病历信息训练的原型，预测起始剂量和最佳治疗剂量之间存在40%的患者之间的误差。与目前奥氮平每天1至80毫克的起始量相比，这是一个显著的减少。抗高血压药物，就像精神药物一样，有很大的治疗选择窗口，包括剂量、药物和使用的治疗组合的显著变化。利用患者信息和在其他地方进行的高血压研究的血液样本，这个第一阶段项目建议应用Generx，将遗传数据与病历表数据结合在一起，在高血压治疗的建模中包括基因数据。每个患者的遗传数据将通过对血液样本中的DNA进行基因分型来获得，根据关键高血压相关基因中是否存在单核苷酸多态(SNPs)进行评分。Generx将根据患者的个体遗传、人口统计和环境变量，预测最初的利尿剂药物或最初的β-受体阻滞剂药物是否有效。一种更有效的降压治疗方法将加速康复，最大限度地减少副作用，降低医疗成本。该项目将在医疗保健管理领域进行商业应用。

This Small Business Innovation Research (SBIR) Phase I project will develop the software platform, GeneRx, to incorporate pharmacogenetics and nonlinear adaptive algorithms toward optimizing anti-hypertension therapy on a patient specific basis. Preliminary studies on the psychotropic drug, olanzapine, show a 40% patient-by-patient error between predicted starting dose and optimal therapeutic dose, using a prototype trained only with patient chart information. This is a significant reduction from the range of starting doses for olanzapine currently used, which is from 1 to 80 mg/day. Anti-hypertensive drugs, like psychotropic drugs, have a large window of therapeutic options, including significant variation in dosages, medications, and combinations of therapies used. Using patient information and blood samples from a hypertension study done elsewhere, this Phase I project proposes to apply GeneRx to include genetic data in the modeling of hypertension treatment in combination with patient chart data. Genetic data for each patient will be acquired by genotyping DNA from the blood samples, scored as single nucleotide polymorphisms (SNPs) present or absent in key hypertension-related genes. GeneRx will take a patient's individual genetic, demographic, and environmental variables and predict if initial diuretic medication or initial beta-blocker medication will be effective. A more efficient method to prescribe effective anti-hypertension therapy would expedite recovery, minimize side effects, and reduce medical costs.The commercial application of this project will be in the field of healthcare management.